ALSO NOTED: Erbitux surge doesn't produce ImClone profit; Glenmark to sell MeyerZall drugs in S. Africa;

> Despite rising Erbitux sales, ImClone Systems lost $916,000 in the third quarter; the culprit was higher operating costs, including a $50 million charge for a patent lawsuit settlement. Report

> Indian drug maker Glenmark Pharmaceuticals has inked a deal with South Africa-based MeyerZall Laboratories to market a handful of topical dermatology drugs in that country. Report

> Celgene almost doubled its profits in the third quarter, to $38.8 million from $20.4 million the same period last year; revenues were up by $104 million to $349.9 million. Report

> Belgium-based Galapagos shares shot up 12 percent on news that the company has inked a massive deal with Jassen Pharmaceutica, a division of Johnson & Johnson. Report

> The FDA has issued an approvable letter for Noven Pharmaceutical's Stavzor, a treatment for manic episodes associated with bipolar disorder, an adjunctive therapy in multiple seizure types, and prophylaxis of migraine headaches. Report

And Finally... One way to help wipe out scary drug-resistant staph? Screen patients as they enter the hospital. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.